The Limited Times

Now you can see non-English news...

The GSK laboratory sees its net profit decline in the third quarter but raises its forecasts

2021-10-27T12:08:05.548Z

The British pharmaceutical group GlaxoSmithKline (GSK) saw its net profit group share fall 6% in the third quarter despite a ...



The British pharmaceutical group GlaxoSmithKline (GSK) saw its net profit group share decline 6% in the third quarter despite an increase in turnover due in particular to high taxes, but raised its forecasts.

Its net profit stood at 1.17 billion pounds on sales up 5% year on year to 9.08 billion pounds, according to a statement Wednesday.

Read alsoAfter GSK, the Elliott fund is interested in the British energy supplier SSE

Emma Walmsley, CEO of the group, particularly welcomed "

double-digit growth in pharmaceuticals and vaccines, the rise of the consumer health branch and the maintenance of discipline on costs

".

These results have enabled us "

to improve our annual forecasts and (...) strengthen our confidence in the prospects for a radical change in growth and performance in 2022 and beyond,

" she said.

No vaccine against covid-19

GSK now expects adjusted earnings per share in 2021 to drop between 2% to 4% excluding the contribution of its solutions against Covid-19 which "

represents an improvement over the previous estimate of July 2021

" .

Shortly before 11:30 a.m. GMT, GSK shares rose 2.37% to 1,468.20 pence on the London Stock Exchange.

The good reception of these figures on the stock market plays in favor of Mrs. Walmsley, contested by two investment funds which ask for his departure, criticize his balance sheet and in particular the mediocre performance of the action since his arrival.

Read alsoA new investment fund calls for the replacement of the head of GSK

GSK is also criticized for not having yet brought a vaccine against Covid-19 to the market.

The group announced at the end of August the launch with the South Korean SK Bioscience of advanced phase 3 trials for a candidate vaccine against Covid-19, very late in particular on the British Astrazeneca.

Source: lefigaro

All business articles on 2021-10-27

Similar news:

You may like

News/Politics 2021-10-29T07:26:28.206Z

Trends 24h

Business 2021-11-23T09:46:58.574Z

Latest

© Communities 2019 - Privacy